Skip to content
value.today

Innospec Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Fewer than two of the last three years have both cash from operations and capital spending on file.

P/EP/E of Chemicals: $1.6 B to $5.0 B, median $2.8 BPrice to salesPrice to sales of Chemicals: $1.2 B to $6.1 B, median $3.0 BPrice to bookPrice to book of Chemicals: $1.6 B to $7.6 B, median $3.0 B$0 M$2.1 B$4.1 B$6.2 B$8.2 BMarket value $2.4 B

Your own DCF model

A full discounted-cash-flow model of Innospec Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Chemicals

Multiples of its companies with a market value at most 60 days old, times Innospec Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Innospec Inc.Applied toValue (25th to 75th)Companies
P/E13.5× / 24.2× / 43.1×17.2×net income $117 M$1.6 B to $5.0 B80
Price to sales0.7× / 1.7× / 3.4×1.3×revenue $1.8 B$1.2 B to $6.1 B96
Price to book1.2× / 2.3× / 5.8×1.8×book equity $1.3 B$1.6 B to $7.6 B95

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Innospec Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

19.9×

Now below its median of 20.6×; range 15.3× to 108.1× over 27 months.

0×27×54×81×108×2020202120222023202420252026P/E 20×Median 21×

Price to sales

1.3×

Now above its median of 1.2×; range 1.0× to 3.5× over 30 months.

0×1×2×3×3×2020202120222023202420252026Price to sales 1×Median 1×

Price to book

1.8×

Now above its median of 1.7×; range 1.4× to 5.0× over 29 months.

0×1×3×4×5×2020202120222023202420252026Price to book 2×Median 2×

as of Oct 20, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 20, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$1.8 B$117 M$138 M———SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$1.8 B$36 M$185 M———SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$1.9 B$139 M$207 M———SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$2.0 B$133 M$82 M———SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$1.5 B$93 M$93 M———SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$1.2 B$29 M$146 M——$-105 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $2.4 B on Oct 20, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.